Albuquerque and San Diego, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics Announces Evidence Development Agreement with a Large Mid-Atlantic Health Insurer for the AVISE® Lupus Test, see full press release here.
http://www.prnewswire.com/news-releases/carefirst-and-exagen-diagnostics-announce-evidence-development-agreement-for-avise-lupus-diagnostic-test-300699103.html
Exagen Diagnostics Announces Evidence Development Agreement with a Large Mid-Atlantic Health Insurer for the AVISE® Lupus Test
| Source: Exagen Diagnostics, Inc.
Recommended Reading
-
Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% CARLSBAD, Calif., Nov. 10, 2026 ...
Read More -
Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17
Read More